Selecting Patients for Immunotherapy in CSCC: Key Considerations

Why It Matters

Earlier immunotherapy integration can improve survival and reduce recurrence in CSCC, addressing a disease driven by immune mechanisms. The shift also creates new market opportunities for checkpoint inhibitor manufacturers and demands coordinated care pathways.

Key Takeaways

• Immunotherapy now considered earlier for moderate‑risk, resectable CSCC.
• Multidisciplinary teams assess neoadjuvant or adjuvant checkpoint inhibitors.
• Organ transplant patients risk graft rejection with PD‑1 blockers.
• Cosibelimab shows promise as a safer immunotherapy alternative.
• NCCN guidelines endorse systemic therapy evaluation beyond low‑risk cases.

Pulse Analysis

Cutaneous squamous cell carcinoma remains one of the most common skin cancers in the United States, with an estimated 1.8 million new cases annually. Historically, surgery has been the definitive treatment for low‑risk lesions, while advanced disease relied on radiation or systemic chemotherapy. Recent insights into the tumor’s immunogenic nature have sparked a paradigm shift, positioning checkpoint inhibition as a frontline strategy even before disease becomes unresectable. This evolution reflects broader oncology trends where immune‑based therapies are moving earlier in treatment algorithms.

The National Comprehensive Cancer Network now recommends that multidisciplinary tumor boards evaluate systemic immunotherapy for patients with moderate‑risk or technically resectable CSCC. Neoadjuvant checkpoint inhibitors can shrink tumors, potentially allowing less extensive surgery, while adjuvant use aims to eradicate microscopic disease and lower recurrence rates. Real‑world data suggest response rates exceeding 50 % in selected cohorts, prompting clinicians to incorporate dermatologists, surgeons, medical oncologists, and radiation specialists into shared decision‑making processes. Such collaboration ensures that tumor size, resectability, and patient comorbidities are balanced against the benefits of immune activation.

Special populations present nuanced challenges. Organ‑transplant recipients, for example, face heightened graft‑rejection risk when exposed to PD‑1 inhibitors, limiting the applicability of standard agents. Newer molecules like cosibelimab, a PD‑L1 inhibitor with a distinct safety profile, are under investigation and may offer a viable alternative. Ongoing trials of intralesional immunotherapy also hint at future options for early‑stage disease, potentially reducing the need for extensive surgery. As evidence accumulates, payers and providers will need to adapt reimbursement models and care pathways to accommodate these emerging therapies, reinforcing the strategic importance of early immunotherapy adoption in CSCC.